FDA Permits Last-Resort Iclusig Use After Clinical Trial Deaths
Two months after announcing a spate of deaths, the U.S. Food and Drug Administration on Friday allowed Ariad Pharmaceuticals Inc. to resume sales of leukemia drug Iclusig to a narrower universe...To view the full article, register now.
Already a subscriber? Click here to view full article